Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27129579.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0582.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 3710-2. ©2016 AACRSee related article by Bossi et al., p. 3961.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Gene Expression Regulation, Neoplastic
- Head and Neck Neoplasms
- Transcriptome